Search results for " SIT"

showing 10 items of 2985 documents

The acute myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve blockades.

2003

Bupivacaine causes muscle damage. However, the myotoxic potency of ropivacaine is still unexplored. Therefore, we performed this study to compare the effects of bupivacaine and ropivacaine on skeletal muscle tissue in equipotent concentrations. Femoral nerve catheters were inserted into anesthetized minipigs, and 20 mL of either bupivacaine (5 mg/mL) or ropivacaine (7.5 mg/mL) was injected. Subsequently, bupivacaine (2.5 mg/mL) and ropivacaine (3.75 mg/mL) were continuously infused over 6 h. Control animals were treated with corresponding volumes of normal saline. Finally, muscle samples were dissected at injection sites. After processing and staining, histological patterns of muscle damage…

medicine.medical_specialtyTissue Fixationmedicine.drug_classSwinemedicine.medical_treatmentMyotoxinMuscle Fibers SkeletalFemoral nerveMuscular DiseasesPeripheral nervemedicineIn Situ Nick-End LabelingAnimalsEdemaRopivacainePeripheral NervesAnesthetics LocalMuscle SkeletalBupivacaineLocal anestheticbusiness.industryRopivacaineNerve BlockAmidesBupivacaineSurgeryMicroscopy ElectronAnesthesiology and Pain MedicineAnesthesiaToxicityNerve blockSwine MiniatureFemalebusinessmedicine.drugAnesthesia and analgesia
researchProduct

Are we really seeing the total costs of surgical site infections? A Spanish study.

2007

To identify overall costs generated by surgical site infections (SSI) patients, including indirect costs. A prospective study of case series of patients who have undergone major surgical treatment was undertaken. Patients who suffered SSI were compared with controls (nested case-control design). Centers for Disease Control and Prevention definitions were followed and SSI established. Overall costs and indirect related morbidity/mortality costs were estimated. The study was performed in a general, tertiary hospital (Valencia, Spain) for 4.5 years. Surgical site infections patients were 9.02% of the total people who underwent surgery. Their stays were prolonging by 14 days, and resources were…

medicine.medical_specialtyTotal costbusiness.industryDermatologyLength of Staymedicine.diseaseDisease controlIndirect costsCost of IllnessSpainEmergency medicineHealth careSurgical siteCost of illnessmedicineHumansSurgical Wound InfectionSurgeryMedical emergencyHospital CostsbusinessSurgical treatmentProspective cohort studyhealth care economics and organizationsWound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
researchProduct

Developmental expression of human cartilage matrix protein.

1994

Cartilage matrix protein (CMP) is a non-collagenous component of cartilage with a yet unknown function. In this study we used in situ hybridization to investigate the temporal and sptial distribution of CMP transcripts during human embryonic and early fetal development, and compared it to the pattern of expression observed for collagen types I, II, X, and decorin. The distribution of CMP and collagen type II transcripts followed a similar pattern in the embryonic bone anlage, the fetal growth plate, and the developing vertebral column. Expression was highest in the upper hypertrophic and lower proliferative zone, whereas calcified cartilage was negative throughout the different stages of bo…

medicine.medical_specialtyTranscription GeneticDecorinBiologyMatrix (biology)Cartilage Oligomeric Matrix ProteinKidneyChondrocyteBone and BonesExtracellular matrixEmbryonic and Fetal DevelopmentInternal medicinemedicinePerichondriumHumansMatrilin ProteinsRNA MessengerIn Situ HybridizationGlycoproteinsSkinExtracellular Matrix ProteinsCartilageCell DifferentiationDNAChondrogenesisSpineCell biologycarbohydrates (lipids)Collagen type I alpha 1Endocrinologymedicine.anatomical_structureCartilagePhenotypeJointsProteoglycansCollagenDecorinDevelopmental BiologyDevelopmental dynamics : an official publication of the American Association of Anatomists
researchProduct

Induction of gamma-globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients.

2008

Increased expression of fetal haemoglobin (HbF) may ameliorate the clinical course of beta-thalassemia and sickle cell disease. Some pharmacological agents, such as hydroxycarbamide (HC), can increase fetal haemoglobin synthesis during adult life. Cellular selection and/or molecular mechanisms have been proposed to account for this increase. To explore the mechanism of action of HC we focused on homozygous Hb-Lepore patients that presented with high fetal haemoglobin levels and were good responders to HC treatment "in vivo". We performed primary erythroid cultures from peripheral blood of four homozygous Lepore patients. The increase in HBG (gamma-globin) transcription levels and HbF conten…

medicine.medical_specialtyTranscription GeneticHemoglobins AbnormalBiologyBlood cellHydroxycarbamideErythroid CellsTranscription (biology)hemic and lymphatic diseasesInternal medicineFetal hemoglobinmedicineHumansHydroxyureaGlobinRNA MessengerCells CulturedFetal HemoglobinIn Situ Hybridization FluorescenceHematologybeta-ThalassemiaHematologyMolecular biologyGlobinsRed blood cellmedicine.anatomical_structureCell culturemedicine.drugBritish journal of haematology
researchProduct

Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6- and glutathione-dependent mechanism

2013

[EN] Background: Interleukin (IL)-6 (mainly of tumor origin) activates glutathione (GSH) release from hepatocytes and its interorgan transport to B16-F10 melanoma metastatic foci. We studied if this capacity to overproduce IL-6 is regulated by cancer cell-independent mechanisms. Methods: Murine B16-F10 melanoma cells were cultured, transfected with red fluorescent protein, injected i.v. into syngenic C57BL/6J mice to generate lung and liver metastases, and isolated from metastatic foci using high-performance cell sorting. Stress hormones and IL-6 levels were measured by ELISA, and CRH expression in the brain by in situ hybridization. DNA binding activity of NF-kappa B, CREB, AP-1, and NF-IL…

medicine.medical_specialtyTranscription GeneticMelanoma ExperimentalInterleukin 6ApoptosisEnzyme-Linked Immunosorbent AssayIn situ hybridizationBiologyMetastasesCREBReal-Time Polymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyFlow cytometryMiceNorepinephrineAdrenocorticotropic HormoneInternal medicineCell Line TumormedicineAnimalsNeoplasm MetastasisIn Situ HybridizationMedicine(all)medicine.diagnostic_testBase SequenceBiochemistry Genetics and Molecular Biology(all)Interleukin-6ResearchStress hormonesInterleukinGeneral MedicineTransfectionCell sortingMolecular biologyGlutathionehumanitiesEndocrinologyElectroporationApoptosisbiology.proteinCorticosteroneDNA ProbesHormoneTranscription FactorsJournal of Translational Medicine
researchProduct

Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma

2001

Abstract Patients with mantle cell lymphoma (MCL) may present with either nodal or leukemic disease. The molecular determinants underlying this different biologic behavior are not known. This study compared the pattern of genetic abnormalities in patients with nodal and leukemic phases of MCL using comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) for specific gene loci. Although both leukemic and nodal MCL showed similar genomic patterns of losses (involving 6q, 11q22-q23, 13q14, and 17p13) and gains (affecting 3q and 8q), genomic loss of chromosome 8p occurred more frequently in patients with leukemic disease (79% versus 11%,P < .001). Subsequent…

medicine.medical_specialtyTumor suppressor geneImmunologyGenes mycLocus (genetics)Lymphoma Mantle-CellBiologyBiochemistryMYC Gene AmplificationGene duplicationmedicineHumansGenes Tumor SuppressorIn Situ Hybridizationmedicine.diagnostic_testGene AmplificationCytogeneticsNucleic Acid HybridizationCell BiologyHematologyPrognosismedicine.diseaseCancer researchMantle cell lymphomaGene DeletionChromosomes Human Pair 8Fluorescence in situ hybridizationComparative genomic hybridizationBlood
researchProduct

Intravesical Treatment of Superficial Urinary Bladder Tumours with Adriamycin

1980

Personal experience resulted in the observation that intravesical Adriamycin (ADM) is effective in some patients with multiple or diffuse papillary bladder tumours. A review of the literature shows that similar results have been obtained elsewhere, especially in Japan and Sweden. The response rate was higher if single doses of at least 50 mg were employed. Intravesical instillations of ADM appear to be valuable also in the treatment of carcinoma in situ and in prophylactic treatment after transurethral resection (TUR) of papillary bladder tumours.

medicine.medical_specialtyUrinary bladderbusiness.industryCarcinoma in situUrologymedicine.diseaseResectionNeck of urinary bladderTransitional cell carcinomaIntravesical treatmentmedicine.anatomical_structureIntravesical instillationmedicinebusinessProphylactic treatment
researchProduct

Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell…

1996

Objectives. To evaluate a selected population of 50 consecutive patients with primary T1, G3 bladder transitional cell carcinoma in the absence of carcinoma in situ (Tis) treated with a bladder-sparing approach. Methods. Between January 1983 and December 1992, all patients were treated by transurethral resection (TUR) plus adjuvant intravesical chemotherapy over 1 year. In most cases, doxorubicin, epirubicin, and mitomycin were used alone or in combination. Results. At a mean follow-up period of 52 months (range, 18 to 126), 16 of 50 patients (32%) showed a recurrent superficial tumor. The recurrent lesion was of Stage T1 in 11 (22%) cases, but was a T1, G3 tumor only in 5 cases (10%). In 2…

medicine.medical_specialtyUrologymedicine.medical_treatmentPopulationAntineoplastic AgentsMitomycinsSettore MED/24 - UrologiaCystectomyUrethraCarcinomamedicineHumansBACILLUS CALMETTE-GUERINeducationEpirubicinNeoplasm StagingCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryCarcinoma in situmedicine.diseaseCombined Modality TherapyCANCERSurgeryAdministration Intravesicalmedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinSurgical Procedures OperativeNeoplasm Recurrence LocalbusinessFollow-Up StudiesEpirubicinmedicine.drugUrology
researchProduct

ICUD-EAU International Consultation on Bladder Cancer 2012: Non–Muscle-Invasive Urothelial Carcinoma of the Bladder

2012

Item does not contain fulltext CONTEXT: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. OBJECTIVE: To critically review the recent data on the management of NMIBC to arrive at a general consensus. EVIDENCE ACQUISITION: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. EVIDENCE SYNTHESIS: The major findi…

medicine.medical_specialtyUrologymedicine.medical_treatmentUrologyMEDLINEAntineoplastic AgentsContext (language use)Aetiology screening and detection [ONCOL 5]CystectomyQuality of Care [ONCOL 4]Molecular epidemiology [NCEBP 1]CystectomyTranslational research [ONCOL 3]medicineHumansNeoplasm InvasivenessProspective cohort studyNeoplasm StagingBladder cancermedicine.diagnostic_testbusiness.industryGeneral surgeryCarcinoma in situCystoscopymedicine.diseaseAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsBCG VaccineDisease ProgressionNeoplasm GradingNeoplasm Recurrence LocalUrotheliumbusinessIntravesical chemotherapyCarcinoma in SituEuropean Urology
researchProduct

Potential role of the neuropeptide CGRP in the induction of differentiation of rat hepatic portal vein wall.

2005

The media of the rat hepatic portal vein is composed of an internal circular muscular layer (CL) and an external longitudinal muscular layer (LL). These two perpendicular layers differentiate progressively from mesenchymal cells within the first month after birth. In this paper, we studied the development of calcitonin gene-related peptide (CGRP) innervation during post-natal differentiation of the vessel. We show that CGRP innervation is already present around the vessel at birth in the future adventitia but far from the lumen of the vessel. Progressively, CGRP immunoreactive fibers reached first LL then CL. CL by itself become only innervated at day 14 after birth. This corresponds to the…

medicine.medical_specialtyVascular smooth musclePhysiologyCalcitonin Gene-Related PeptideRecombinant Fusion ProteinsImmunocytochemistryMyocytes Smooth MuscleGene ExpressionCalcitonin gene-related peptideBiologyTransfectionBiochemistryMuscle Smooth VascularCell LineMuscular layerCellular and Molecular NeuroscienceMiceEndocrinologyInternal medicineAdventitiaMyosinmedicineAnimalsHumansRats WistarLuciferasesPromoter Regions GeneticBinding SitesMyosin Heavy ChainsPortal VeinNeuropeptidesAge FactorsCell DifferentiationImmunohistochemistryRatsEndocrinologymedicine.anatomical_structureLiverConnective TissueDesminHepatic portal veinRabbitsPeptides
researchProduct